Cytena
Freiburg
About Cytena
cytena GmbH has developed a device called cy-Clone to separate single cells. Single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research. The cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. Thanks to this particularly gentle delivery method, the cells are able to survive post printing and can either be analyzed thereafter or grown into clonal colonies. To determine clonality, multiple images are recorded during the process. Cross-contamination is avoided by the use of disposable parts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $4.6M
- Funding stage: M&A
- Last round: Series A (Mar 2019)
- Website: cytena.com
- Phone: +004976120373260
Industries & Categories
Biotechnology, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/cytena-60382 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.